Relationship between retinoic acid receptor α gene expression and growth-inhibitory effect of all-trans retinoic acid on canine tumor cells

Journal of Veterinary Internal Medicine

Volumn 20, Issue 2, 2006, Pages 348-354

  Miyajima, Nozomi ^a   Watanabe, Manabu ^b   Ohashi, Emi ^a   Mochizuki, Manabu ^a   Nishimura, Ryohei ^a   Ogawa, Hiroyuki ^a   Sugano, Sumio ^b   Sasaki, Nobuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

ATRA; Dog; Real time quantitative polymerase chain reaction; Retinoid

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA;

ANIMAL; ANIMAL DISEASE; ARTICLE; CELL PROLIFERATION; DOG; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; NEOPLASMS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRETINOIN;

CANIS FAMILIARIS;

EID: 33645575824     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[348:RBRARG]2.0.CO;2     Document Type: Article

References (34)

1. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-954.
2. Petkovich M, Brand NJ, Krust A, et al. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987;330:444-450.
3. Giguere V, Ong ES, Segui P, et al. Identification of a receptor for the morphogen retinoic acid. Nature 1987;330:624-629.
4. Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
5. Mangelsdorf DJ, Borgmeyer U, Heyman RA, et al. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 1992;6:329-344.
6. Tallman MS. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-1028.
7. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-193.
8. Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002;16:421-429.
9. Fountzilas G. Retinoids in the management of head and neck cancer: an update. J Chemother 1994;6:127-138.
10. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000;10:393-406.
11. Kelly WK, Osman I, Reuter VE, et al. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin Cancer Res 2000;6:838-846.
12. Lawrence JA, Adamson PC, Caruso R, et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol 2001;19:2754-2763.
13. Rohde D, Brkovic D, Honig d'Orville I. All-trans retinoic acid and interferon-α for treatment of human renal cell carcinoma multicellular tumor spheroids. Urol Int 2004;73:47-53.
14. DiGiovanna JJ. Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 2001;36:564-567.
15. Reynolds CP, Matthay KK, Villablanca JG. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-192.
16. White SD, Rosychuk RA, Scott KV, et al. Sebaceous adenitis in dogs and results of treatment with isotretinoin and etretinate: 30 cases (1990-1994). J Am Vet Med Assoc 1995;207:197-200.
17. Marks SL, Song MD, Stannard AA, et al. Clinical evaluation of etretinate for the treatment of canine solar-induced squamous cell carcinoma and preneoplastic lesions. J Am Acad Dermatol 1992;27:11-16.
18. White SD, Rosychuk RA, Scott KV, et al. Use of isotretinoin and etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs. J Am Vet Med Assoc 1993;202:387-391.
19. Thamm DH, Vail DM. Mast cell tumors. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology, 3rd ed. Philadelphia, PA: WB Saundars; 2001;2001:261-282.
20. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
21. Hong SH, Kadosawa T, Nozaki K, et al. In vitro retinoid-induced growth inhibition and morphologic differentiation of canine osteosarcoma cells. Am J Vet Res 2000;61:69-73.
22. Ohashi E. In Vitro Antitumor Activity of Retinoids on Canine Cancer Cells. Doctoral thesis, the University of Tokyo, Japan.
23. Ohashi E, Inoue K, Kagechika H, et al. Effect of natural and synthetic retinoids on the proliferation and differentiation of three canine melanoma cell lines. J Vet Med Sci 2002;64:169-172.
24. Miyajima N, Watanabe M, Ohashi E, et al. Identification and characterization of a canine highly similar to retinoic acid receptor α. DNA Seq 2005;16:7-15.
25. Uyama R. Establishment of canine and feline mammary grand tumor cell lines and expressions of E-cadherin, α-, β-, and γ-catenins. Doctoral thesis.
26. Hong SH, Kadosawa T, Mochizuki M, et al. Establishment and characterization of two cell lines derived from canine spontaneous osteosarcoma. J Vet Med Sci 1998;60:757-760.
27. Kadosawa T, Nozaki K, Sasaki N, et al. Establishment and characterization of a new cell line from a canine osteosarcoma. J Vet Med Sci 1994;56:1167-1169.
28. Inoue K, Ohashi E, Kadosawa T, et al. Establishment and characterization of four canine melanoma cell lines. J Vet Med Sci 2004;66:1437-1440.
29. Ohashi E, Hong SH, Takahashi T, et al. Effect of retinoids on growth of two canine melanoma cell lines. J Vet Med Sci 2001;63:83-86.
30. Ishiguro T, Kadosawa T, Mori K, et al. Establishment and characterization of a new canine mast cell tumor cell line. J Vet Med Sci 2001;63:1031-1034.
31. Takahashi T, Kitani S, Nagase M, et al. IgG-mediated histamine release from canine mastocytoma-derived cells. Int Arch Allergy Immunol 2001;125:228-235.
32. Tyler RD, Cowell RL, Baldwin CJ, et al. Microscopic evaluation, and interpretation. In: Cowell RL, Tyler RD, Meinkoth JH, eds. Diagnostic Cytology and Hematology of the Dog and Cat, 2nd ed. St. Louis (MO): Mosby; 1999:11-13.
33. Wen J, Wang L, Zhang M, et al. Repression of telomerase activity during in vitro differentiation of osteosarcoma cells. Cancer Invest 2002;20:38-45.
34. Peng X, Yun D, Christov K. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids. Int J Oncol 2004;25:961-971.